RCT | Rezvilutamide vs. Bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer.

Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial – The Lancet Oncology

Commentaries:

Treatment options for metastatic hormone-sensitive prostate cancer – The Lancet Oncology

Rezvilutamide benefits shown in metastatic hormone-sensitive prostate cancer – medwire News

Commentary on Twitter

In a preplanned interim analysis of the phase III CHART trial in pts with high-volume mHSPC, rezvilutamide +ADT improve PFS (HR 0.44, 95% CI 0.33–0·.8; P<0.0001) & OS (HR 0.58, 95% CI 0.44–0.77]; P=0.0001) compared with bicalutamide + ADT: https://t.co/42IVnDUxfH #PCSM #uroonc

— NatureRevClinOncol (@NatRevClinOncol) September 7, 2022